Hepatic tissues, including bile canaliculi and sinusoids, around primary or metastatic tumors are destructed and regenerate associated with tumor growth, and may show some phenotypic changes. The present study was undertaken to examine the expression of CD10 in bile canaliculi [CD10(BC)] and CD105 (endoglin) along hepatic sinusoids [CD105(HS)] in peritumoral hepatic tissue (PTH).
Methods
Fifty samples of resected liver bearing hepatocellular carcinoma (HCC) or metastatic carcinoma were immunostained for CD10 and CD105. The immunoreactivity for CD10(BC) and CD105(HS) in the background hepatic tissue of tumors and PTH was scored separately.
Results
CD10(BC) was moderately or markedly expressed in the background hepatic tissue without chronic hepatitis or cirrhosis in most of the cases, and was significantly downregulated in chronic hepatitis and cirrhosis. CD105(HS) was negative or minimally positive in most of the cases of hepatic tissue bearing metastatic carcinoma, and showed a significant increase in chronic hepatitis and cirrhosis. Compared with the background, PTH revealed significantly decreased CD10(BC) staining irrespective of HCC or metastatic carcinoma, and showed belt-like CD105(HS) expression in 66.7% of the cases of metastatic carcinoma and in 88.6% of those with HCC.
Conclusions
These data indicate that the expression patterns of CD10(BC) and CD105(HS) in PTH are similar to those in chronic hepatitis and cirrhosis, which may be caused by persistent injury and resultant regeneration of hepatic tissue.
NakamuraT., HayamaM., SakaiT., HotchiM., TanakaE.: Proliferative activity of hepatocytes in chronic viral hepatitis as revealed by immunohistochemistry for proliferating nuclear cell antigen. Hum Pathol, 24: 750–753, 1993.
2.
FarinatiF., CardinR., D'ErricoA., De MariaN., NaccaratoR., CecchettoA., GrigioniW.: Hepatocyte proliferative activity in chronic liver damage as assessed by the monoclonal antibody MIB1 Ki67 in archival material: the role of etiology, disease activity, iron, and lipid peroxidation. Hepatology, 23: 1468–1475, 1996.
3.
KaitaK.D., PettigrewN., MinukG.Y.: Hepatic regeneration in humans with various liver disease as assessed by Ki-67 staining of formalin-fixed paraffin-embedded liver tissue. Liver, 17: 13–16, 1997.
4.
NakamuraT., HotchiM.: Changes in DNA strand breaks in non-parenchymal cells following hepatocyte regeneration in CCl4-induced rat liver injury. Virchows Arch B, 63: 11–16, 1992.
5.
TaniguchiE., SakisakaS., MatsuoK., TanikawaK., SataM.: Expression and role of vascular endothelial growth factor in liver regeneration after partial hepatectomy in rats. J Histochem Cytochem, 49: 121–130, 2001.
6.
BorscheriN., RoessnerA., RockenC.: Canalicular staining of neprilysin (CD10) as a diagnostic marker of hepatocellular carcinoma. Am J Surg Pathol, 25: 1297–1303, 2001.
7.
RockenC., LichtJ., RoessnerA., Carl-McGrathS.: Canalicular immunostaining of aminopeptidase N (CD13) as a diagnostic marker for hepatocellular carcinoma. J Clin Pathol, 58: 1069–1075, 2005.
8.
McIntoshG.G., LodgeA.J., WatsonP., HallA.G., WoodK., AndersonJ.J., AngusB., HorneC.H., MiltonI.D.: NCL-CD10-270: A new monoclonal antibody recognizing CD10 in paraffin-embedded tissue. Am J Pathol, 154: 77–82, 1999.
9.
ShippM.A., StefanoG.B., SwitzerS.N., GriffinJ.D., ReinherzE.L.: CD10 (CALLA) neutral endopeptidase 24.11 modulates inflammatory peptide-induced changes in neutrophil morphology, migration, and adhesion proteins and is itself regulated by neutrophil activation. Blood, 78: 1834–1841, 1991.
10.
LebienT.W., McCormackR.T.: The common acute lymphoblastic leukemia antigen (CD10): emancipation from a functional enigma. Blood, 73: 625–635, 1989.
11.
BorellaL., SenL., CasperJ.T.: Acute lymphoblastic leukemia (ALL) antigens detected with antisera to E rosette-forming and non-E rosette forming ALL blasts. J Immunol, 118: 309–315, 1977.
12.
ChuP., ArberD.A.: Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am J Clin Pathol, 113: 374–382, 2000.
13.
ChuP.G., IshizawaS., WuE., WeissL.M.: Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein. Am J Surg Pathol, 26: 978–988, 2002.
14.
MorrisonC., MarshW.Jr., FrankelW.L.: A comparison of CD10 to pCEA, MOC-31, and hepatocyte for the distinction of malignant tumors in the liver. Mod Pathol, 15: 1279–1287, 2002.
15.
ShoushaS., GadirF., PestonD., BansiD., ThillainaygamA.V., Murray-LyonI.M.: CD10 immunostaining of bile canaliculi in liver biopsies: change of staining pattern with the development of cirrhosis. Histopathology, 45: 335–342, 2004.
16.
DuffS.E., LiC., GarlandJ.M., KumarS.: CD105 is important for angiogenesis: evidence and potential applications. FASEB J, 17: 984–992, 2003.
17.
FonsattiE., MaioM.: Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. J Transl Med, 2: 18, 2004.
18.
HoJ.W., PoonR.T., SunC.K., XueW-C, FanS-T.: Clinicopathological and prognostic implications of endoglin (CD105) expression in hepatocellular carcinoma and its adjacent non-tumorous liver. World J Gastroenterol, 11: 176–181, 2005.
19.
YuJ-X, ZhangX-T, LiaoY-Q, ZhangQ-Y, ChenH., LinM., KumarS.: Relationship between expression of CD105 and growth factors in malignant tumors of gastrointestinal tract and its significance. World J Gastroenterol, 9: 2866–2869, 2003.
20.
SalvesenH.B., GulluogluM.G., StefanssonI., AkslenL.A.: Significance of CD105 expression for tumor angiogenesis and prognosis in endometrial carcinoma. APMIS, 111: 1011–1018, 2003.
21.
SaadR.S., LiuY.L., NathanG., CelebrezzeJ., MedichD., SilvermanJ.F.: Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol, 17: 197–203, 2004.
22.
KyzasP.A., AgnantisN.J., StefanouD.: Endoglin (CD105) as a prognostic factor in head and neck squamous cell carcinoma. Virchows Arch, 448: 768–775, 2006.
23.
FonsattiE., SigalottiL., ArslanP., AltomonteM., MaioM.: Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies. Curr Cancer Drug Targets, 3: 427–432, 2003.
24.
FonsattiE., AltomonteM., NicotraM.R., NataliP.G., MaioM.: Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene, 22: 6557–6563, 2003.
25.
ChungY.C., HouY.C., PanA.C.: Endoglin (CD105) expression in the development of hemorrhoids. Eur J Clin Invest, 34: 107–112, 2004.
26.
TasmanF., DagdevirenA., KendirB., ErN., AtacA.: Endothelial cell and stromal antigens in human periapical granulation tissue. J Endod, 26: 81–84, 2000.
27.
TorsneyE., CharltonR., ParumsD., CollisM., ArthurH.M.: Inducible expression of human endoglin during inflammation and wound healing in vivo. Inflamm Res, 51: 464–470, 2002.
28.
ZhangE.G., SmithS.K., Charnock-JonesD.S.: Expression of CD105 (endoglin) in arteriolar endothelial cells of human endometrium throughout the menstrual cycle. Reproduction, 124: 703–711, 2002.
29.
Garcia-MonzonC., Sanchez-MadridF., Garcia-BueyL., Garcia-ArroyoA., Garcia-SanchezA., Moreno-OteroR.: Vascular adhesion molecule expression in viral chronic hepatitis: evidence of neoangiogenesis in portal tracts. Gastroenterology, 108: 231–241, 1995.
30.
AsanzaC.G., Garcia-MonzonC., ClementeG., SalcedoM., Garcia-BueyL., Garcia-IglesiasC., BanaresR., AlvarezE., Moreno-OteroR.: Immunohistochemical evidence of immunopathogenetic mechanisms in chronic hepatitis C recurrence after liver transplantation. Hepatology, 26: 755–763, 1997.
31.
ClementeM., NunezO., LorenteR., RinconD., MatillaA., SalcedoM., CatalinaM.V., RipollC., IaconoO.L., BanaresR., ClementeG., Garcia-MonzonC.: Increased intrahepatic and circulating levels of endoglin, a TGF-α co-receptor, in patients with chronic hepatitis C virus infection: relationship to histological and serum markers of hepatic fibrosis. J Viral Hepat, 13: 625–632, 2006.
32.
YuD., ZhuangL., SunX., ChenJ., YaoY., MengK., DingY.: Particular distribution and expression pattern of endoglin (CD105) in the liver of patients with hepatocellular carcinoma. BMC Cancer, 7: 122, 2007.
